Golden logo
    Create a WorkspaceQuery ToolSaved QueriesData RequestsListsPipelinesExploreFollowed Topics
    Upgrade to ProPricingAPI AccessHelp & Support
Log in
Sign up
NEW: You can now make knowledge queries using our new natural language prompt. Try it out now!
⟶
SpringWorks Therapeutics

SpringWorks Therapeutics

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that takes a precision medicine approach in acquiring, developing and commercializing medicines for patient populations that are suffering from rare diseases and cancer.

OverviewStructured DataIssuesContributorsActivity
Contents

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that takes a precision medicine approach in acquiring, developing and commercializing medicines for patient populations that are suffering from rare diseases and cancer.

Its lead pipeline programs are in potentially registrational clinical trials for rare oncology indications. Nirogacestat, its gamma secretase inhibitor, is in a Phase 3 clinical trial for treating desmoid tumors, which are rare and often debilitating and disfiguring soft-tissue tumors.

Mirdametinib, its MEK inhibitor, is in a Phase 2b clinical trial for treating adults and children with neurofibromatosis type 1-associated plexiform neurofibromas (NF1-PN), which are peripheral nerve sheath tumors that cause severe pain, disfigurement and shortened life span.

SpringWorks is advancing, in partnership with industry leaders, several other programs addressing highly prevalent, genetically defined cancers, including evaluating nirogacestat as a cornerstone of BCMA combination therapy for patients with several myeloma and several efforts in RAS and RAF-mutated solid tumors with advanced precision medicine approaches for these types of cancer.

Timeline

April 2019
SpringWorks Therapeutics raises a $125,000,000 series B round from ArrowMark Partners, Biotechnology Value Fund, GlaxoSmithKline, HBM Healthcare Investments AG, Laurion Capital Management, LifeArc, OrbiMed, Samsara BioCapital, Surveyor Capital and Tavistock Group.
April 1, 2019
SpringWorks Therapeutics raises a $125,000,000 series B round from Perceptive Advisors.
September 2017
SpringWorks Therapeutics raises a $103,000,000 series A round from Bain Capital Double Impact, Bain Capital Life Sciences, LifeArc, OrbiMed and Pfizer.

Funding Rounds

Open in Query Tool

Patents

Open in Query Tool

Further Resources

Title
Author
Link
Type
Date

References

springworkstx.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Therapeutics
Therapeutics
Biomedical engineering
Biomedical engineering
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Engineering
Engineering
Location
Stamford, Connecticut
Stamford, Connecticut
Durham, North Carolina
Durham, North Carolina
B2X
B2C
B2C
CEO
‌
Saqib Islam, J.D.
Founder
Lara S. Sullivan
Lara S. Sullivan
Pitchbook URL
pitchbook.com/profiles...185814-01
Legal Name
SpringWorks Therapeutics, Inc.
Legal classification
Public company
Public company
Number of Employees (Ranges)
100 – 249
Number of Employees
190
Full Address
100 Washington Blvd Stamford, CT 06902, USA
5310 S. Alston Avenue Durham, NC 27713, USA
CIK Number
1,773,427
Place of Incorporation
Delaware
Delaware
Investors
Laurion Capital Management
Laurion Capital Management
Bain Capital
Bain Capital
Surveyor Capital
Surveyor Capital
Bain Capital Life Sciences
Bain Capital Life Sciences
Bain Capital Double Impact
Bain Capital Double Impact
Biotechnology Value Fund (BVF Partners)
Biotechnology Value Fund (BVF Partners)
LifeArc
LifeArc
Pfizer
Pfizer
...
Founded Date
2017
Email Address
careers@springworkstx.com
info@springworkstx.com
investors@springworkstx.com
media@springworkstx.com
medinfo@springworkstx.com
partnering@springworkstx.com
iir@springworkstx.com
Phone Number
+19847773500
+12038839490
Total Funding Amount (USD)
353,000,000
Latest Funding Round Date
April 1, 2019
Stock Symbol
SWTX
Exchange
Nasdaq
Nasdaq
Glassdoor ID
3047160
Board of Directors
‌
Saqib Islam, J.D.
‌
Alan Fuhrman
‌
Julie Hambleton
‌
Jeffrey Schwartz
‌
Stephen Squinto
CFO
‌
Francis I. Perier Jr
Latest Funding Type
Series B round
Series B round
Patents Assigned (Count)
1
COO
‌
Badreddin Edris

Other attributes

Headquarters
Stamford, Connecticut
Stamford, Connecticut
Country
United States
United States
Company Operating Status
Active
Ticker Symbol
SWTX
SIC Code
2,836
Golden logo
Company
HomePress & MediaBlogCareers
We're hiring
Products
OverviewKnowledge GraphQuery ToolData RequestsKnowledge StorageAPIPricingEnterpriseProtocol
Legal
Terms of ServiceEnterprise Terms of ServicePrivacy Policy
Help
Help centerAPI DocumentationContact Us
By using this site, you agree to our Terms of Service.